| Loraine Marie Torres Garcia, | |
|
1845 Carr 2 Ste 307, Bayamon, PR 00959-7203 | |
| (787) 622-0829 | |
| Not Available |
| Full Name | Loraine Marie Torres Garcia |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 1845 Carr 2 Ste 307, Bayamon, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730684895 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 22599 (Puerto Rico) | Primary |
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275556946 PECOS PAC ID: 8527972827 Enrollment ID: O20040605000314 |
News Archive
Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
A nationwide study of 2.3 million Israeli adolescents, examined from 1967 through 2010, finds an association between elevated body-mass index in late adolescence, and subsequent cardiovascular mortality in midlife.
› Verified 5 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487677159 PECOS PAC ID: 8527972827 Enrollment ID: O20040721000677 |
News Archive
Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
A nationwide study of 2.3 million Israeli adolescents, examined from 1967 through 2010, finds an association between elevated body-mass index in late adolescence, and subsequent cardiovascular mortality in midlife.
› Verified 5 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578586244 PECOS PAC ID: 8527972827 Enrollment ID: O20040803000311 |
News Archive
Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
A nationwide study of 2.3 million Israeli adolescents, examined from 1967 through 2010, finds an association between elevated body-mass index in late adolescence, and subsequent cardiovascular mortality in midlife.
› Verified 5 days ago
| Entity Name | Salud Integral En La Montana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316970833 PECOS PAC ID: 8527972827 Enrollment ID: O20040806000074 |
News Archive
Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
A nationwide study of 2.3 million Israeli adolescents, examined from 1967 through 2010, finds an association between elevated body-mass index in late adolescence, and subsequent cardiovascular mortality in midlife.
› Verified 5 days ago
| Entity Name | Dra Loraine Torres Garcia Obgyn Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093436032 PECOS PAC ID: 3173990264 Enrollment ID: O20221102001341 |
News Archive
Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
A nationwide study of 2.3 million Israeli adolescents, examined from 1967 through 2010, finds an association between elevated body-mass index in late adolescence, and subsequent cardiovascular mortality in midlife.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Loraine Marie Torres Garcia, J4 Ave San Patricio Apt 14, Guaynabo, PR 00968-4485 Ph: (787) 679-3740 | Loraine Marie Torres Garcia, 1845 Carr 2 Ste 307, Bayamon, PR 00959-7203 Ph: (787) 622-0829 |
News Archive
Myriad Pharmaceuticals, Inc. today announced several strategic initiatives to focus the Company's efforts on its oncology pipeline and to conserve its financial resources to extend the Company's projected cash runway beyond 2013.
Researchers in Canada have conducted a study suggesting that the majority of patients living with long COVID (coronavirus disease) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) experience chronic fatigue that is at least as severe as that seen in several other clinical conditions.
Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.
A nationwide study of 2.3 million Israeli adolescents, examined from 1967 through 2010, finds an association between elevated body-mass index in late adolescence, and subsequent cardiovascular mortality in midlife.
› Verified 5 days ago
Edilberto Martinez, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 73 Calle Santa Cruz, Edif. Medico Santa Cruz Suite 413, Bayamon, PR 00961 Phone: 787-269-1445 Fax: 787-787-2808 | |
Nilda M Vazquez, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Edif Arturo Cadilla Torre San Pablo, Suite 211, Bayamon, PR 00960 Phone: 787-273-1227 | |
Dilaury Mejia Berrios, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Instituto San Pablo Ste510, #66 Calle Santa Cruz, Bayamon, PR 00961 Phone: 787-787-1088 Fax: 787-786-3398 | |
Dr. Eumari Salicrup-zayas, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Metro Medical Center, Suite 301 Torre B, Bayamon, PR 00959 Phone: 787-269-0040 Fax: 787-269-3185 | |
Edwin Baez Montalvo, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Ave Aguas Buenas, Bloq 16 #34 Urb Santa Rosa, Bayamon, PR 00959 Phone: 787-798-0344 Fax: 787-740-4266 | |
Dr. Luis E Ramos Rodriguez, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 73 Calle Santa Cruz Ste 102, Edificio Medico Santa Cruz, Bayamon, PR 00961 Phone: 787-740-3565 Fax: 787-740-3625 | |
Mireily Rivera Rosado, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: Carimed Plz Ste 505b-1, Bayamon, PR 00961 Phone: 787-955-6292 |